LXRX | InformativeNASDAQ:LXRX
Technical Analysis for LXRX:
If LXRX breaks above the bullish line of $4.00, it may indicate a bullish signal and suggest potential upward price movement. In this scenario, the target prices (TP) could be set at $4.50 and $6.00 as bullish targets.
Conversely, if LXRX breaks below the bearish line of $2.87, it may suggest a bearish signal and imply potential downward price movement. The target prices (TP) for the bearish scenario could be set at $2.33 and $1.70.
It is important to consider other technical factors, such as the formation of a double top, Elliott Wave theory movements, and RSI overbought condition, which may indicate a potential pullback before the breakout. The double top pattern suggests a potential reversal, while Elliott Wave theory can provide insights into the price's wave-like movements. These factors should be taken into account when analyzing LXRX's price action. And the pull back price target could be at 3.29$ area.
Fundamental Analysis for LXRX:
LXRX is a biopharmaceutical company that develops innovative therapies for patients with metabolic diseases. The company's pipeline includes potential treatments for diabetes, hypercholesterolemia, and fatty liver disease. LXRX leverages its expertise in lipid metabolism to address unmet medical needs and improve patient outcomes.
LXRX's financial performance and market position are influenced by the success of its drug candidates in clinical trials and the potential for regulatory approval. Positive clinical trial results and successful regulatory milestones can significantly impact the company's stock price.
It is important to consider potential risks associated with the biopharmaceutical industry, including the uncertain outcome of clinical trials, regulatory challenges, and competitive pressures. The success of LXRX's drug candidates depends on factors such as efficacy, safety, and market acceptance. Additionally, changes in healthcare policies and reimbursement practices could affect the commercial potential of LXRX's products.
However, LXRX's focus on metabolic diseases and its pipeline of potential therapies position the company for potential growth opportunities. The successful development and commercialization of its drug candidates could lead to increased market share and revenue growth in the long term.
Please note that this analysis is based on the available information and market conditions at the time of writing. It is important to conduct further research and analysis before making any investment decisions.
LXRX
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX
LXRX has gained over 100% in the past month
However it appears to be forming a double top
in a potential short trade setup on the two hour chart.
The K/D crossover on the hot RSI oscillator provides
confirmation.
Short Sale Volume is rising in the past two days.
Findamentals - LXRX has a new medication for heart failure
a common medical problem with a massive market
It recently launched a public offering to raise capital
to fund general operations and in doing so
diluted the share holders. The good news is
it is unlikely to do another in the near term.
An entry would be at the current price with a stop loss
above the highest volume bar on the profile.
The first target is the POC of the volume profile
about a 15% price drop . The second target is
the pivot low on August 1st for another 15% drop.
Taking of 1/2 at each target yields an expected
23% return over a period of about 5 trading days
since drops are faster than rises.
The call options of mid September have low volumes
so I will not consider them.
Swingtrade examples for breakoutsJust like TXMD, I like Lexicon too. BB is an indicator that even though I don't rely on, but together with RSI -and some other factors and market conditions- it's not a bad idea to consider looking at it. The vertical lines represent the buy and sell moments on this chart, please note where the price was at those points on the Bollinger Band and what value we saw on the RSI. (BTW, I bought at $1.26)
So, not a rule oc, (but interesting data we have in front of us) that where with the green fat arrows I was pointing to are the prices at the lower B.band + "oversold" RSI levels, these usually result in a breakout especially if the band is contracted (called the squeeze) and the other way around similarly, when price was at the higher band + "overbought" RSI more likely than not is followed by a correction (price drop). Just an observation of a few decades.
*sorry about the typos
LXRX - a gain again?Possibility to gain again?
It looks like it want to crawl up on a support line (green).
I've packed bags here a little.
Indicators are almost reversed to bullish.
But it still can go lower if it breaks the support line.
Remember to have a stop loss below the support line.
There is a big gap below 5.60.
There also could happen a bear trap, quick fall and then quick retrace and skyrocketing.
This one is going to be fun soon.
But Reward/Risk ratio is promising.
1st target point is 7.60(+over 30% profit).
fundamentally : beating almost every estimations lately.
Good luck!
LXRX - Bullish But Risky Move. Pullback ComingLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
SHORT INTEREST
7.74M 08/15/19
P/E Current
-1.51
P/E Ratio (with extraordinary items)
-2.05
Average Recommendation: OVERWEIGHT
Average Target Price: 8.00